Features | Partner Sites | Information | LinkXpress
Sign In
BioConferenceLive
JIB
GLOBETECH PUBLISHING

New Application Note Addresses Benefits of aCGH/SNP Cancer Research Arrays

By BiotechDaily International staff writers
Posted on 10 Apr 2013
Image: CytoSure Cancer +SNP arrays from Oxford Gene Technology (Photo courtesy of Oxford Gene Technology.)
Image: CytoSure Cancer +SNP arrays from Oxford Gene Technology (Photo courtesy of Oxford Gene Technology.)
A new application note on combined array comparative genomic hybridization (aCGH) and single nucleotide polymorphism (SNP) arrays is now available to support researchers in navigating the combined approach for the simultaneous detection of copy number variations (CNVs) and runs of homozygosity (ROH).

The application note, titled “Detecting copy number variants and runs of homozygosity on a single array — challenges and applications” is provided by Oxford Gene Technology (OGT; Oxfordshire, UK). aCGH has been established as the “gold-standard” platform for array-based CNV detection. Recent advances have enabled the combination of aCGH probes for CNV detection with probes able to detect SNPs. Particularly well suited for clinical genetics researchers, the application note highlights the importance and benefits of these combined probe arrays in the detection of various genetic conditions. For example, OGT’s CytoSure aCGH +SNP arrays allow any reference DNA to be used and no restriction digest of the sample is required. This enables labeling and hybridization steps to be completed in a single day (unlike typical SNP platforms) while providing information on changes in copy number and regions of homozygosity, and integrating into existing workflows.

The OGT arrays have been research-validated to provide informative, biologically relevant SNP data for various genetic aberrations such as uniparental disomy (UDP), mosaic aneuploidy and ROH, without compromising on high-quality CNV data. CytoSure aCGH +SNP arrays are available for constitutional, cancer, and molecular genetics research. Each array also comes with complimentary access to OGT’s “CytoSure Interpret Software,” a powerful, user-friendly CNV and SNP data analysis package, which contains innovative features to minimize user intervention and maximize consistency and speed of data interpretation.

Related Links:
Oxford Gene Technology
Application note


comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Microcomputed tomography images (top) and histology images (bottom) of the knees of mice fed a very high fat diet containing omega-3 fatty acid supplement (left) or only omega-6 fatty acids (right) after a knee injury. The omega-6 diet showed abnormal bone remodeling and calcified tissue formation in the joint (white arrow). The omega-6 diet also showed significant loss of cartilage (red staining, yellow arrowhead) and increased joint inflammation (Photo courtesy of Duke University).

Dietary Omega-3 Fatty Acids Moderate Severity of Osteoarthritis in a Mouse Model

Researchers working with an osteoarthritis (OA) obese mouse model found that the fat content of the animals' diet contributed more to the development or arrest of OA than did body weight.... Read more

Drug Discovery

view channel
Image: Molecular rendering of the crystal structure of parkin (Photo courtesy of Wikimedia Commons).

Cinnamon Feeding Blocks Development of Parkinson's Disease in Mouse Model

A team of neurological researchers has identified a molecular mechanism by which cinnamon acts to protect neurons from damage caused by Parkinson's disease (PD) in a mouse model of the syndrome.... Read more

Therapeutics

view channel

Vaccine Being Developed for Heart Disease Close to Reality

The world’s first vaccine for heart disease is becoming a possibility with researchers demonstrating significant arterial plaque reduction in concept testing in mice. Klaus Ley, MD, from the La Jolla Institute for Allergy and Immunology (LA Jolla, CA, USA), and a vascular immunology specialist, is leading the vaccine... Read more

Business

view channel

A Surge in IPOs Revitalize Investments for the Global Pharma and Biotech

Anti-infective drugs, oncology, and pharmaceutical contract laboratories attract the most investment up to now. The intensified private equity and venture capital (PEVC) deal activity in the global healthcare industry during the recession years, 2008–2010, witnessed a waning post-2010. However, the decline in deals... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.